BRIEF

on Viromed Medical AG (isin : DE000A3MQR65)

Viromed Medical AG Partners with NEBU-TEC to Distribute PulmoPlas®

Viromed Medical AG has announced an exclusive distribution partnership with NEBU-TEC for their PulmoPlas® product. This collaboration focuses on veterinary applications, particularly targeting respiratory diseases in horses. The agreement grants NEBU-TEC global distribution rights, aiming to leverage their nebulization technology with Viromed's cold plasma solutions.

Viromed's CEO, Uwe Perbandt, emphasized that this partnership is crucial for the international expansion of PulmoPlas®. Eike Kern of NEBU-TEC highlighted the potential therapeutic benefits of integrating inhalation devices with cold plasma technology. The market launch is slated for later in 2026, with a focus on the European equine market where there's significant demand for respiratory treatments.

The devices used by NEBU-TEC comply with EU Medical Device Regulation, allowing potential future use in human medicine. This partnership is set to position Viromed's technology in new international markets, advancing its strategic presence in the cold plasma field.

R. H.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Viromed Medical AG news